Reducing Cognitive Decline and Dementia Risk: Evidence-Based Guidelines Released by WHO

The World Health Organization (WHO) released updated evidence-based guidelines on reducing the risk of cognitive decline and dementia, providing countries with evidence-based recommendations to help prevent or delay the onset of dementia across the life course. Dementia is a condition caused by brain diseases and affects memory, thinking and the ability to function. More than 57 million people live with dementia worldwide and nearly 10 million people get newly diagnosed every year. The framework aims to reduce the long-term clinical and economic burden of cognitive decline, which currently costs the global economy an estimated US$ 1.3 trillion per year.

• Up to 45% of dementia risk is associated with modifiable factors, including hypertension, diabetes, physical inactivity, and air pollution.
• Routine supplementation with vitamins B, E, omega-3 fatty acids, or multivitamins is not recommended for dementia prevention in the absence of a diagnosed clinical deficiency.

Epidemiological Shift and Pathogenesis Considerations

Dementia is a condition caused by brain diseases and affects memory, thinking and the ability to function. Alzheimer’s disease remains the most prevalent etiology, accounting for 60–70% of identified cases.

Evidence-Based Interventions and Lifestyle Modifications

The current guidelines represent a significant expansion of the 2019 recommendations, incorporating growth in the evidence base on environmental and behavioral health. Clinical practitioners are advised to encourage cognitive training, social engagement, and physical activity for adults with normal cognition or those presenting with mild cognitive impairment.

The management of cardiometabolic health is a central pillar of this prevention strategy. Unmanaged diabetes and high blood pressure create systemic vascular damage that correlates strongly with an increased risk of vascular dementia and Alzheimer’s disease.

Clinical Guidance on Supplementation and Auditory Health

One of the most notable aspects of the updated guidance is the explicit recommendation against the use of dietary supplements—specifically vitamins B and E, omega-3 polyunsaturated fatty acids (PUFA), and multivitamins—for dementia prevention in the absence of documented deficiencies. Evidence indicates that these interventions lack clinical efficacy in cognitive preservation and may, in certain populations, carry risks of adverse effects. Conversely, the guidelines acknowledge the role of hearing health, suggesting that the use of hearing aids may serve as an effective intervention strategy for those experiencing age-related hearing loss, which is often comorbid with social isolation and cognitive decline.

Economic and Socio-Clinical Implications

The economic impact of dementia is substantial, with approximately 50% of the US$ 1.3 trillion annual global cost attributed to unpaid caregiving. By shifting the clinical focus toward risk reduction, the WHO aims to empower member states to integrate mental health and NCD services more cohesively. This systemic integration is intended to reduce the burden on both healthcare infrastructure and the families who provide the majority of long-term care.

For healthcare providers and administrative leads looking to align their practices with these latest international standards, rigorous compliance with updated clinical pathways is essential.

The trajectory of dementia research increasingly favors a life-course approach, where early identification of modifiable risk factors serves as the primary defense against the progression of cognitive impairment. As the evidence base continues to mature, the focus will remain on translating clinical guidelines into actionable, patient-centered care that prioritizes independence and long-term quality of life.